GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genmab A/S GMAB.CO · DKK

Health Care · Nasdaq Copenhagen · 🇩🇰 Denmark

Compare

3,661.00

+3.80%

Close of 9 Nov 2026, in DKK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$592.6m

FY2016FY2025

Net income

$153.4m

FY2016FY2025

Free cash flow

$183.0m

FY2016FY2025

Shareholders' equity

$895.7m

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$592.6m$3.30bn$2.53bn$2.23bn$1.30bn$1.55bn$823.8m$464.4m$363.1m$278.8m
Gross profit$543.3m$3.15bn$2.49bn$2.23bn$1.30bn$1.55bn$823.8m$464.4m$363.1m$278.8m
Research and development$248.3m$1.50bn$1.17bn$853.9m$641.9m$481.6m$366.3m$219.7m$134.2m$101.5m
Operating income$199.1m$1.08bn$816.9m$968.0m$453.4m$969.2m$405.0m$211.9m$206.4m$161.6m
Net income$153.4m$1.20bn$668.1m$837.0m$454.0m$730.5m$332.5m$226.0m$169.4m$182.2m
Diluted earnings per share2.2818.8310.1012.656.9411.205.193.682.683.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$1.97bn$7.03bn$5.42bn$4.62bn$3.78bn$3.25bn$2.32bn$1.30bn$1.01bn$804.2m
Cash and short-term investments$262.7m$3.24bn$4.32bn$3.43bn$2.97bn$2.47bn$1.68bn$937.4m$832.5m$602.1m
Total liabilities$1.08bn$1.40bn$564.8m$435.5m$373.2m$310.4m$168.3m$68.6m$50.8m$63.2m
Debt$851.7m$158.0m$118.2m$91.7m$65.2m$49.0m$27.8m——$9.5m
Shareholders' equity$895.7m$5.63bn$4.85bn$4.19bn$3.41bn$2.94bn$2.16bn$1.23bn$962.9m$741.0m
Shares outstanding67m64m66m66m65m65m64m61m63m60m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$188.9m$1.19bn$1.13bn$600.6m$342.0m$987.6m$203.6m$155.8m$243.9m$50.3m
Capital spending−$5.9m−$28.7m−$57.7m−$48.7m−$38.7m−$47.1m−$17.0m−$73.3m−$13.6m−$5.1m
Free cash flow$183.0m$1.16bn$1.08bn$551.9m$303.4m$940.5m$186.5m$82.5m$230.4m$45.2m

Financial ratios

Data as of 29 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin91.7%95.4%98.6%100.0%100.0%100.0%
Operating margin33.6%32.5%32.3%43.5%34.8%62.4%
Net margin25.9%36.4%26.4%37.6%34.9%47.1%
Return on equity17.1%21.4%13.8%20.0%13.3%24.9%
Return on assets7.8%17.1%12.3%18.1%12.0%22.5%
Free cash flow yield0.8%5.4%5.1%2.8%1.6%4.5%
Revenue growth-82.1%30.7%13.6%71.0%-16.1%88.4%
Earnings growth-87.3%80.2%-20.2%84.4%-37.9%119.7%
Current ratio2.02x5.25x13.34x15.48x14.50x15.00x
Debt to equity0.91x0.01x0.00x0.00x0.00x0.00x
Equity ratio45.4%80.1%89.6%90.6%90.1%90.4%
Interest coverage20.49x58.36x197.07x300.24x227.15x631.30x
R&D as a share of sales41.9%45.3%46.3%38.3%49.3%31.0%
Buybacks as a share of market value-5.2%3.3%0.0%-1.2%-0.3%-1.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-35.7%-17.5%13.0%
Operating income-41.0%-27.1%5.9%
Net income-43.2%-26.8%2.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin94.9%97.3%98.0%98.3%
Operating margin32.7%35.4%38.9%41.0%
Net margin34.8%33.1%35.2%37.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings141.012.633.936.960.134.945.346.060.861.3
Price to sales36.54.68.913.920.916.418.322.428.440.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.